RB1 and neoplasm: Targeted NGS analysis of AH samples collected from treatment-naive primary enucleated eyes (PE) determined that our capture-based NGS assay could detect 94% of RB1 pathogenic variants previously identified by clinical testing of the paired genomic and/or tumour DNA.